Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fractyl HealthGUTS +1.15%11 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates GUTS with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 703 Biotechnology companies, Fractyl Health ranks worse than 142247.37% on this metric.
The historical data trend for Fractyl Health's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Fractyl Health's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fractyl Health Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fractyl Health's Days Payable distribution charts can be found below:
* The bar in red indicates where Fractyl Health's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Fractyl Health's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fractyl Health (GUTS) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Fractyl Health and its competitors. Over the past decade, Fractyl Health's Days Payable has ranged from 3,633.41 to 13,844.45. According to the industry distribution chart, Fractyl Health ranks #999999 out of 703 companies in the Biotechnology industry.
Is Fractyl Health's Days Payable too high?
Fractyl Health's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 3,633.41 to a high of 13,844.45. Based on the distribution chart, Fractyl Health ranks #999999 out of 703 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Fractyl Health has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Fractyl Health's Days Payable compare to ENGN and ANIX?
According to the Biotechnology industry distribution chart, Fractyl Health ranks #999999 out of 703 companies for Days Payable. This places Fractyl Health in the lower half of its industry. The industry median Days Payable is 112.61. Historically, Fractyl Health's own Days Payable has ranged from 3,633.41 to 13,844.45 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.61, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Fractyl Health and its competitors. For the Biotechnology industry, the median Days Payable is 112.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fractyl Health's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fractyl Health stock overvalued right now?
Fractyl Health (GUTS) has a current Days Payable of 0.00. The current Days Payable is 0.00. Fractyl Health's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Fractyl Health (GUTS), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Fractyl Health Inc is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D). Its Revita and Rejuva candidates are designed to target root causes of metabolic diseases, allowing the company to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease. The Revita DMR System (Revita), its lead product candidate, is based on its insights surrounding the potential role of the gut in obesity.
11GF Score
Get the complete analysis for GUTS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GUTS has been successfully added to your 
